Paper41301162
Mesenchymal Stem Cell-Mediated Targeted Drug Delivery Systems for Hepatocellular Carcinoma: Current Advances and Future Directions.
Gao Y and 4 others. Bioengineering (Basel), 2025. Cited by 2 papers, by iCite.
Cite this record
ConductScience Library. Mesenchymal Stem Cell-Mediated Targeted Drug Delivery Systems for Hepatocellular Carcinoma: Current Advances and Future Directions. Papers, record 41301162. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41301162
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Mesenchymal Stem Cell-Mediated Targeted Drug Delivery Systems for Hepatocellular Carcinoma: Current Advances and Future Directions.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
Grants4
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| 82172599 | National Natural Science Foundation of China | PubMed | ||
| 82170143 | National Natural Science Foundation of China | PubMed | ||
| 82370191 | National Natural Science Foundation of China | PubMed | ||
| 82200160 | National Natural Science Foundation of China | PubMed |
Source PubMed
References156
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 35133380 | Engineered mesenchymal stem cell-derived exosomes with high CXCR4 levels for targeted siRNA gene therapy against cancer. | Nanoscale | 2022 | https://conductscience.org/library/papers/35133380 | PubMed |
| 2 | 37752117 | Combined FOLFOX4 with all-trans retinoic acid versus FOLFOX4 with placebo in treatment of advanced hepatocellular carcinoma with extrahepatic metastasis: a randomized, double-blind comparative study. | Signal Transduct Target Ther | 2023 | https://conductscience.org/library/papers/37752117 | PubMed |
| 3 | 36652132 | Human umbilical cord mesenchymal stem cell-derived exosomes carrying miR-1827 downregulate SUCNR1 to inhibit macrophage M2 polarization and prevent colorectal liver metastasis. | Apoptosis | 2023 | https://conductscience.org/library/papers/36652132 | PubMed |
| 4 | 39806451 | Emerging role of exosomes in cancer therapy: progress and challenges. | Mol Cancer | 2025 | https://conductscience.org/library/papers/39806451 | PubMed |
| 5 | 33527831 | Treatment for Hepatocellular Carcinoma Is Enhanced When Norcantharidin Is Encapsulated in Exosomes Derived from Bone Marrow Mesenchymal Stem Cells. | Mol Pharm | 2021 | https://conductscience.org/library/papers/33527831 | PubMed |
| 6 | 40696139 | Heat stress targets and degrades BCR::ABL1 oncoproteins to overcome drug-resistance in Philadelphia chromosome-positive acute lymphoblastic leukemia. | Leukemia | 2025 | https://conductscience.org/library/papers/40696139 | PubMed |
| 7 | 32483419 | CXCR4 mediates matrix stiffness-induced downregulation of UBTD1 driving hepatocellular carcinoma progression via YAP signaling pathway. | Theranostics | 2020 | https://conductscience.org/library/papers/32483419 | PubMed |
| 8 | 36261831 | Tumor buster - where will the CAR-T cell therapy 'missile' go? | Mol Cancer | 2022 | https://conductscience.org/library/papers/36261831 | PubMed |
| 9 | 38402155 | Ultrasonic microbubbles promote mesenchymal stem cell homing to the fibrotic liver via upregulation of CXCR4 expression. | Cell Div | 2024 | https://conductscience.org/library/papers/38402155 | PubMed |
| 10 | 39261846 | Engineering exosomes derived from TNF-α preconditioned IPFP-MSCs enhance both yield and therapeutic efficacy for osteoarthritis. | J Nanobiotechnology | 2024 | https://conductscience.org/library/papers/39261846 | PubMed |
| 11 | 40683482 | Nuclear receptors in metabolism and diseases: Mechanistic and therapeutic insights. | Pharmacol Res | 2025 | https://conductscience.org/library/papers/40683482 | PubMed |
| 12 | 34929349 | Management of hepatocellular carcinoma recurrence after liver transplantation. | Ann Hepatol | 2022 | https://conductscience.org/library/papers/34929349 | PubMed |
| 13 | 19654411 | Mesenchymal stromal cells cross-present soluble exogenous antigens as part of their antigen-presenting cell properties. | Blood | 2009 | https://conductscience.org/library/papers/19654411 | PubMed |
| 14 | 36817457 | Improved efficacy of mesenchymal stromal cells stably expressing CXCR4 and IL-10 in a xenogeneic graft versus host disease mouse model. | Front Immunol | 2023 | https://conductscience.org/library/papers/36817457 | PubMed |
| 15 | 40703618 | Amphiphilic lipid-peptide engineered placenta-derived mesenchymal stem cells for liver fibrosis treatment. | Asian J Pharm Sci | 2025 | https://conductscience.org/library/papers/40703618 | PubMed |
| 16 | 36100944 | Mesenchymal stem cell-derived exosomes in cancer therapy resistance: recent advances and therapeutic potential. | Mol Cancer | 2022 | https://conductscience.org/library/papers/36100944 | PubMed |
| 17 | 26073566 | Mesenchymal stem cells and adaptive immune responses. | Immunol Lett | 2015 | https://conductscience.org/library/papers/26073566 | PubMed |
| 18 | 38299924 | Nanotechnology and bioengineering approaches to improve the potency of mesenchymal stem cell as an off-the-shelf versatile tumor delivery vehicle. | Med Res Rev | 2024 | https://conductscience.org/library/papers/38299924 | PubMed |
| 19 | 34838121 | Amplification of spatially isolated adenosine pathway by tumor-macrophage interaction induces anti-PD1 resistance in hepatocellular carcinoma. | J Hematol Oncol | 2021 | https://conductscience.org/library/papers/34838121 | PubMed |
| 20 | 39636740 | Energy Stress-Induced circEPB41(2) Promotes Lipogenesis in Hepatocellular Carcinoma. | Cancer Res | 2025 | https://conductscience.org/library/papers/39636740 | PubMed |
Cited by3
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 2 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42861321 | Drug Delivery Systems for Hepatocellular Carcinoma: Bridging Pathophysiological Barriers and Advanced Nanomedicine Strategies. | Drug Des Devel Ther | 2026 | https://conductscience.org/library/papers/42861321 | PubMed |
| 42338608 | Rearming mesenchymal stem cells with engineering strategies to combat cancer. | Front Immunol | 2026 | https://conductscience.org/library/papers/42338608 | PubMed |
| 41847179 | Nanotechnology-Enabled Diagnosis and Treatment of Hepatocellular Carcinoma: Theranostics, Combination Regimens, and Translation. | Int J Nanomedicine | 2026 | https://conductscience.org/library/papers/41847179 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41301162
GET https://conductscience.org/api/papers/v1/41301162/references?page=2